185.52MMarket Cap-4341P/E (TTM)
0.731High0.681Low3.32MVolume0.689Open0.680Pre Close2.33MTurnover2.09%Turnover RatioLossP/E (Static)255.88MShares2.05052wk High2.32P/B115.04MFloat Cap0.43052wk Low--Dividend TTM158.68MShs Float21.570Historical High--Div YieldTTM7.28%Amplitude0.420Historical Low0.701Avg Price1Lot Size
Adaptimmune Therapeutics Stock Forum
● Cash / liquidity position: As of September 30, 2024, Adaptimmune had cash and cash equivalents of $116.7 million and Total Liquidity2 of $186.1 million, compared to $144.0 million and $146.9 million respectively, as of December 31...
On September 23, 2024, Adaptimmune Therapeutics plc (the “Company”) entered into a Mutual Release and Resolution Agreement (the “Agreement”) with Genentech Inc and F. Hoffmann-La Roche Ltd, (together “Genentech”). The parties entered into the Agreement following notice of termination of their Collaboration and License Agreement dated September 3, 2021 (the “Collaboration Agreement”) on April 8,...
so the spike in cash is from financing, fyi
after the product is approved, profitable, it's your time to shine.
$Adaptimmune Therapeutics (ADAP.US)$
come on
No comment yet